Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 15/20 | 0.56 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MMP7 | P09237 | 1/20 | 0.51 |
| ▸ | MMP10 | P09238 | 1/20 | 0.51 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2223323 | 1.00 | CHRM1 (0.56) | CHRM1ADAM17MMP3MMP7MMP10 | |
| SCHEMBL2363404 | 1.00 | CHRM1 (0.56) | CHRM1ADAM17MMP3MMP7MMP10 | |
| SCHEMBL2222670 | 0.93 | CHRM1 (0.56) | CHRM1ADAM17MMP3MMP7MMP10 | |
| SCHEMBL2222077 | 0.93 | CHRM1 (0.55) | CHRM1ADAM17MMP3MMP7MMP10 | |
| SCHEMBL2221980 | 0.90 | CHRM1 (0.54) | CHRM1ADAM17MMP3MMP7MMP10 | |
| SCHEMBL2221983 | 0.90 | CHRM1 (0.54) | CHRM1ADAM17MMP3MMP7MMP10 | |
| SCHEMBL12803424 | 0.90 | CHRM1 (0.54) | CHRM1ADAM17MMP3MMP7MMP10 | |
| SCHEMBL6890514 | 0.90 | ADAM17 (0.49) | CHRM1ADAM17MMP3MMP7MMP10 | |
| SCHEMBL2351738 | 0.89 | CHRM1 (0.55) | CHRM1ADAM17MMP3MMP7MMP10 | |
| SCHEMBL21873509 | 0.89 | CHRM1 (0.48) | CHRM1PDE2APDE11A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075656-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-17 | — | — | US | claimed |
| US-20160075656-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9199939-B2 | Quinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2512243-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
| WO-2011084368-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252808-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRM2 | CHRM1 1/4885ADAM17 4137/4885MMP3 4505/4885 |
| US-20160075656-A1 | QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRM2 | CHRM1 1/4885ADAM17 4210/4885MMP3 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.